• Rhinitis/rhinorrhea (intranasal products)

Ryaltris Generic Name & Formulations

General Description

Olopatadine (as HCl) 665mcg, mometasone (as furoate monohydrate) 25mcg; per nasal spray.

Pharmacological Class

Antihistamine + corticosteroid.

How Supplied

Spray—29g (240 sprays)

Generic Availability


Mechanism of Action

Olopatadine is a histamine-1 (H1) receptor inhibitor. The antihistaminic activity of olopatadine has been documented in isolated tissues, animal models, and humans. 

Mometasone furoate is a corticosteroid demonstrating potent anti-inflammatory activity. The precise mechanism of corticosteroid action on allergic rhinitis is not known. Corticosteroids have been shown to have a wide range of inhibitory effects on multiple cell types (eg, mast cells, eosinophils, neutrophils, macrophages, and lymphocytes) and mediators (eg, histamine, eicosanoids, leukotrienes, and cytokines) involved in inflammation. 

Ryaltris Indications


Seasonal allergic rhinitis.

Ryaltris Dosage and Administration


Use 2 sprays in each nostril twice daily.


<12yrs: not established.

Ryaltris Contraindications

Not Applicable

Ryaltris Boxed Warnings

Not Applicable

Ryaltris Warnings/Precautions


Risk of epistaxis, nasal ulcerations, nasal septal perforations, impaired nasal wound healing, local Candida infections; monitor periodically. Recent nasal septal ulcers, nasal surgery, or nasal trauma: avoid until healing has occurred. Discontinue if Candida infections or hypersensitivity reactions occur. Monitor closely if change in vision or those with a history of increased intraocular pressure, glaucoma, and/or cataracts. Immunosuppression. Respiratory tract tuberculosis. Infections (eg, fungal, bacterial, viral, ocular herpes simplex). If exposed to measles or chickenpox, may need immunoglobulin or VZIG prophylactic therapy. Hypercorticism. Adrenal suppression. Monitor routinely for growth in children. Hepatic impairment. Pregnancy. Nursing mothers.

Ryaltris Pharmacokinetics


Olopatadine: ~55% human serum protein bound. Mometasone furoate: 98-99% in vitro protein bound.


Olopatadine is not extensively metabolized.


Olopatadine: renal (~70%), fecal (~17%).  Half-life: 9 hours (olopatadine); 18 hours (mometasone furoate).

Ryaltris Interactions


Avoid concomitant alcohol or other CNS depressants. Caution with strong CYP3A4 inhibitors (eg, ketoconazole).

Ryaltris Adverse Reactions

Adverse Reactions

Dysgeusia, epistaxis, nasal discomfort; somnolence, impaired mental alertness.

Ryaltris Clinical Trials

See Literature

Ryaltris Note

Not Applicable

Ryaltris Patient Counseling

See Literature